211427-08-6,MFCD18071356
Catalog No.:AA00BGBV

211427-08-6 | INS 365

Pack Size
Purity
Availability
Price(USD)
Quantity
  
5mg
≥95%
in stock  
$152.00   $106.00
- +
10mg
≥95%
in stock  
$225.00   $157.00
- +
25mg
≥95%
in stock  
$409.00   $286.00
- +
50mg
≥95%
in stock  
$668.00   $467.00
- +
  • Technical Information
  • Properties
  • Literature
  • Request for Quotation
  • Download SDS
Technical Information
Catalog Number:
AA00BGBV
Chemical Name:
INS 365
CAS Number:
211427-08-6
Molecular Formula:
C18H22N4Na4O23P4
Molecular Weight:
878.2344
MDL Number:
MFCD18071356
SMILES:
O[C@@H]1[C@@H](COP(=O)(OP(=O)(OP(=O)(OP(=O)(OC[C@H]2O[C@H]([C@@H]([C@@H]2O)O)n2ccc(=O)[nH]c2=O)[O-])[O-])[O-])[O-])O[C@H]([C@@H]1O)n1ccc(=O)[nH]c1=O.[Na+].[Na+].[Na+].[Na+]
Properties
Computed Properties
 
Complexity:
1460  
Covalently-Bonded Unit Count:
5  
Defined Atom Stereocenter Count:
8  
Defined Bond Stereocenter Count:
0  
Formal Charge:
0  
Heavy Atom Count:
53  
Hydrogen Bond Acceptor Count:
23  
Hydrogen Bond Donor Count:
6  
Isotope Atom Count:
0  
Rotatable Bond Count:
14  
Undefined Atom Stereocenter Count:
0  
Undefined Bond Stereocenter Count:
0  

Literature

Title: Efficacy and safety of diquafosol ophthalmic solution in patients with dry eye syndrome: a Japanese phase 2 clinical trial.

Journal: Ophthalmology 20121001

Title: Clinical evaluation of the additive effect of diquafosol tetrasodium on sodium hyaluronate monotherapy in patients with dry eye syndrome: a prospective, randomized, multicenter study.

Journal: Eye (London, England) 20121001

Title: Diquafosol ophthalmic solution for dry eye treatment.

Journal: Advances in therapy 20120701

Title: Pyrimidine nucleotides with 4-alkyloxyimino and terminal tetraphosphate δ-ester modifications as selective agonists of the P2Y(4) receptor.

Journal: Journal of medicinal chemistry 20110623

Title: Structural modifications of UMP, UDP, and UTP leading to subtype-selective agonists for P2Y2, P2Y4, and P2Y6 receptors.

Journal: Journal of medicinal chemistry 20110428

Title: Denufosol: a review of studies with inhaled P2Y(2) agonists that led to Phase 3.

Journal: Pulmonary pharmacology & therapeutics 20080801

Title: [A molecular marker for dry eye].

Journal: Archivos de la Sociedad Espanola de Oftalmologia 20070301

Title: Double-masked, placebo-controlled safety and efficacy trial of diquafosol tetrasodium (INS365) ophthalmic solution for the treatment of dry eye.

Journal: Cornea 20041101

Title: Diquafosol tetrasodium: a novel dry eye therapy.

Journal: Expert opinion on investigational drugs 20040101

Title: Diquafosol elicits increases in net Cl- transport through P2Y2 receptor stimulation in rabbit conjunctiva.

Journal: Ophthalmic research 20040101

Title: Diquafosol tetrasodium. Inspire/Allergan/Santen.

Journal: Current opinion in investigational drugs (London, England : 2000) 20031101

Title: Molecule of the month. Diquafosol tetrasodium.

Journal: Drug news & perspectives 20031001

Title: Selective P2Y2 receptor agonists stimulate vaginal moisture in ovariectomized rabbits.

Journal: Fertility and sterility 20030201

Title: Diquafosol: DE 089, diquafosol tetrasodium, INS 365, INS 365 Ophthalmic, INS 365 Respiratory, KPY 998.

Journal: Drugs in R&D 20030101

Title: Inhaled P2Y2 receptor agonists as a treatment for patients with Cystic Fibrosis lung disease.

Journal: Advanced drug delivery reviews 20021205

Title: Pharmacology of INS37217 [P(1)-(uridine 5')-P(4)- (2'-deoxycytidine 5')tetraphosphate, tetrasodium salt], a next-generation P2Y(2) receptor agonist for the treatment of cystic fibrosis.

Journal: The Journal of pharmacology and experimental therapeutics 20020901

Title: INS365 suppresses loss of corneal epithelial integrity by secretion of mucin-like glycoprotein in a rabbit short-term dry eye model.

Journal: Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics 20020801

Title: P2Y(2) receptor agonists: a new class of medication targeted at improved mucociliary clearance.

Journal: Chest 20020501

Title: Novel noninvasive sensitive determination of tear volume changes in normal cats.

Journal: Ophthalmic research 20020101

Title: Metabolism and transport of purinergic receptor agonists in rabbit conjunctival epithelial cells.

Journal: Advances in experimental medicine and biology 20020101

Title: Potency and duration of action of synthetic P2Y2 receptor agonists on Schirmer scores in rabbits.

Journal: Advances in experimental medicine and biology 20020101

Title: Ocular safety of INS365 ophthalmic solution, a P2Y2 agonist, in patients with mild to moderate dry eye disease.

Journal: Advances in experimental medicine and biology 20020101

Title: Safety of aerosolized INS 365 in patients with mild to moderate cystic fibrosis: results of a phase I multi-center study.

Journal: Pediatric pulmonology 20010801

Title: Ocular safety of INS365 ophthalmic solution: a P2Y(2) agonist in healthy subjects.

Journal: Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics 20010401

Title: Improvement of corneal barrier function by the P2Y(2) agonist INS365 in a rat dry eye model.

Journal: Investigative ophthalmology & visual science 20010101

Title: The medicinal chemistry of the P2 receptor family.

Journal: Progress in medicinal chemistry 20010101

Title: Lee JH, et al. Comparison of cytotoxicities and wound healing effects of diquafosol tetrasodium and hyaluronic acid on human corneal epithelial cells. Korean J Physiol Pharmacol. 2017 Mar;21(2):189-195.

Title: Fujihara T, et al. Improvement of corneal barrier function by the P2Y(2) agonist INS365 in a rat dry eye model. Invest Ophthalmol Vis Sci. 2001 Jan;42(1):96-100.

Title: Fujihara T, et al. INS365 suppresses loss of corneal epithelial integrity by secretion of mucin-like glycoprotein in a rabbit short-term dry eye model. J Ocul Pharmacol Ther. 2002 Aug;18(4):363-70.

Quotation Request
Company Name:
*
Contact Person:
*
Email:
*
Quantity Required:
*
Country:
Additional Info:
SDS
Tags:211427-08-6 Molecular Formula|211427-08-6 MDL|211427-08-6 SMILES|211427-08-6 INS 365
Catalog No.: AA00BGBV
211427-08-6,MFCD18071356
211427-08-6 | INS 365
Pack Size: 5mg
Purity: ≥95%
in stock
$152.00 $106.00
Pack Size: 10mg
Purity: ≥95%
in stock
$225.00 $157.00
Pack Size: 25mg
Purity: ≥95%
in stock
$409.00 $286.00
Pack Size: 50mg
Purity: ≥95%
in stock
$668.00 $467.00
Quantity
- +
Add to Card
Order Now
bulk Quotation Request
Technical Information
Catalog Number: AA00BGBV
Chemical Name: INS 365
CAS Number: 211427-08-6
Molecular Formula: C18H22N4Na4O23P4
Molecular Weight: 878.2344
MDL Number: MFCD18071356
SMILES: O[C@@H]1[C@@H](COP(=O)(OP(=O)(OP(=O)(OP(=O)(OC[C@H]2O[C@H]([C@@H]([C@@H]2O)O)n2ccc(=O)[nH]c2=O)[O-])[O-])[O-])[O-])O[C@H]([C@@H]1O)n1ccc(=O)[nH]c1=O.[Na+].[Na+].[Na+].[Na+]
Properties
Complexity: 1460  
Covalently-Bonded Unit Count: 5  
Defined Atom Stereocenter Count: 8  
Defined Bond Stereocenter Count: 0  
Formal Charge: 0  
Heavy Atom Count: 53  
Hydrogen Bond Acceptor Count: 23  
Hydrogen Bond Donor Count: 6  
Isotope Atom Count: 0  
Rotatable Bond Count: 14  
Undefined Atom Stereocenter Count: 0  
Undefined Bond Stereocenter Count: 0  
Literature fold

Title: Efficacy and safety of diquafosol ophthalmic solution in patients with dry eye syndrome: a Japanese phase 2 clinical trial.

Journal: Ophthalmology20121001

Title: Clinical evaluation of the additive effect of diquafosol tetrasodium on sodium hyaluronate monotherapy in patients with dry eye syndrome: a prospective, randomized, multicenter study.

Journal: Eye (London, England)20121001

Title: Diquafosol ophthalmic solution for dry eye treatment.

Journal: Advances in therapy20120701

Title: Pyrimidine nucleotides with 4-alkyloxyimino and terminal tetraphosphate δ-ester modifications as selective agonists of the P2Y(4) receptor.

Journal: Journal of medicinal chemistry20110623

Title: Structural modifications of UMP, UDP, and UTP leading to subtype-selective agonists for P2Y2, P2Y4, and P2Y6 receptors.

Journal: Journal of medicinal chemistry20110428

Title: Denufosol: a review of studies with inhaled P2Y(2) agonists that led to Phase 3.

Journal: Pulmonary pharmacology & therapeutics20080801

Title: [A molecular marker for dry eye].

Journal: Archivos de la Sociedad Espanola de Oftalmologia20070301

Title: Double-masked, placebo-controlled safety and efficacy trial of diquafosol tetrasodium (INS365) ophthalmic solution for the treatment of dry eye.

Journal: Cornea20041101

Title: Diquafosol tetrasodium: a novel dry eye therapy.

Journal: Expert opinion on investigational drugs20040101

Title: Diquafosol elicits increases in net Cl- transport through P2Y2 receptor stimulation in rabbit conjunctiva.

Journal: Ophthalmic research20040101

Title: Diquafosol tetrasodium. Inspire/Allergan/Santen.

Journal: Current opinion in investigational drugs (London, England : 2000)20031101

Title: Molecule of the month. Diquafosol tetrasodium.

Journal: Drug news & perspectives20031001

Title: Selective P2Y2 receptor agonists stimulate vaginal moisture in ovariectomized rabbits.

Journal: Fertility and sterility20030201

Title: Diquafosol: DE 089, diquafosol tetrasodium, INS 365, INS 365 Ophthalmic, INS 365 Respiratory, KPY 998.

Journal: Drugs in R&D20030101

Title: Inhaled P2Y2 receptor agonists as a treatment for patients with Cystic Fibrosis lung disease.

Journal: Advanced drug delivery reviews20021205

Title: Pharmacology of INS37217 [P(1)-(uridine 5')-P(4)- (2'-deoxycytidine 5')tetraphosphate, tetrasodium salt], a next-generation P2Y(2) receptor agonist for the treatment of cystic fibrosis.

Journal: The Journal of pharmacology and experimental therapeutics20020901

Title: INS365 suppresses loss of corneal epithelial integrity by secretion of mucin-like glycoprotein in a rabbit short-term dry eye model.

Journal: Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics20020801

Title: P2Y(2) receptor agonists: a new class of medication targeted at improved mucociliary clearance.

Journal: Chest20020501

Title: Novel noninvasive sensitive determination of tear volume changes in normal cats.

Journal: Ophthalmic research20020101

Title: Metabolism and transport of purinergic receptor agonists in rabbit conjunctival epithelial cells.

Journal: Advances in experimental medicine and biology20020101

Title: Potency and duration of action of synthetic P2Y2 receptor agonists on Schirmer scores in rabbits.

Journal: Advances in experimental medicine and biology20020101

Title: Ocular safety of INS365 ophthalmic solution, a P2Y2 agonist, in patients with mild to moderate dry eye disease.

Journal: Advances in experimental medicine and biology20020101

Title: Safety of aerosolized INS 365 in patients with mild to moderate cystic fibrosis: results of a phase I multi-center study.

Journal: Pediatric pulmonology20010801

Title: Ocular safety of INS365 ophthalmic solution: a P2Y(2) agonist in healthy subjects.

Journal: Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics20010401

Title: Improvement of corneal barrier function by the P2Y(2) agonist INS365 in a rat dry eye model.

Journal: Investigative ophthalmology & visual science20010101

Title: The medicinal chemistry of the P2 receptor family.

Journal: Progress in medicinal chemistry20010101

Title: Lee JH, et al. Comparison of cytotoxicities and wound healing effects of diquafosol tetrasodium and hyaluronic acid on human corneal epithelial cells. Korean J Physiol Pharmacol. 2017 Mar;21(2):189-195.

Title: Fujihara T, et al. Improvement of corneal barrier function by the P2Y(2) agonist INS365 in a rat dry eye model. Invest Ophthalmol Vis Sci. 2001 Jan;42(1):96-100.

Title: Fujihara T, et al. INS365 suppresses loss of corneal epithelial integrity by secretion of mucin-like glycoprotein in a rabbit short-term dry eye model. J Ocul Pharmacol Ther. 2002 Aug;18(4):363-70.

Building Blocks More >
212268-44-5
212268-44-5
4-Chloro-7-cyclopentyl-7h-pyrrolo[2,3-d]pyrimidine
AA00BGLW | MFCD09909355
299440-05-4
299440-05-4
2-Hydrazino-5-(trifluoromethyl)-1,3,4-thiadiazole
AA00BGXS | MFCD07786303
217803-89-9
217803-89-9
CefpodoxiMe Proxetil IMpurity E
AA00BHE4
214287-99-7
214287-99-7
(4S)-6-CHLORO-4-((E)-2-CYCLOPROPYLVINYL)-4-(TRIFLUOROMETHYL)-3,4-DIHYDROQUINAZOLIN-2(1H)-ONE
AA00BHR9 | MFCD26960895
27423-82-1
27423-82-1
1H-IMidazole, 4,5-dihydro-2-(3-Methylphenyl)-
AA00BI46 | MFCD09802162
2080-80-0
2080-80-0
Ethyl 3-methyl-1-p-tolyl-1H-pyrazole-5-carboxylate
AA00BICJ | MFCD06408981
206978-14-5
206978-14-5
EPOXYBERGAMOTTIN
AA00BIFV | MFCD16036213
217314-44-8
217314-44-8
2-Fluoro-6-iodo-4-methylaniline
AA00BIUB | MFCD15527690
288251-47-8
288251-47-8
5-Methyl-1-(4-methylphenyl)-1h-pyrazole-4-carboxylic acid
AA00BJ5X | MFCD04122757
25688-18-0
25688-18-0
1-(3-Nitrophenyl)-1h-pyrazole
AA00BJLW | MFCD12192642
Submit
© 2017 AA BLOCKS, INC. All rights reserved.